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Abstract
Background: One particularly exciting field of research involves the use of gold nanoparticles (GNPs) in the
detection and treatment of cancer cells in the liver. The detection and treatment of cancer is an area in which the
light absorption and emission characteristics of GNPs have become useful. Currently, there are no data available
regarding the fluorescence spectra or in vivo accumulation of nanoparticles (NPs) in rat liver after repeated
administration. In an attempt to characterise the potential toxicity or hazards of GNPs in therapeutic or diagnostic
use, the present study measured fluorescence spectra, bioaccumulation and toxic effects of GNPs at 3 and 7 days
following intraperitoneal administration of a 50 μl/day dose of 10, 20 or 50 nm GNPs in rats.
Methods: The experimental rats were divided into one normal group (Ng) and six experimental groups (G1A, G1B,
G2A, G2B, G3A and G3B; G1: 20 nm; G2: 10 nm; G3: 50 nm; A: infusion of GNPs for 3 days; B: infusion of GNPs for 7
days). A 50 μl dose of GNPs (0.1% Au by volume) was administered to the animals via intraperitoneal injection, and
fluorescence measurements were used to identify the toxicity and tissue distribution of GNPs in vivo. Seventy
healthy male Wistar-Kyoto rats were exposed to GNPs, and tissue distribution and toxicity were evaluated after 3 or
7 days of repeated exposure.
Results: After administration of 10 and 20 nm GNPs into the experimental rats, two fluorescence peaks were
observed at 438 nm and 487 nm in the digested liver tissue. The fluorescence intensity for 10 and 20 nm GNPs
(both first and second peaks) increased with the infusion time of GNPs in test rats compared to normal rats. The
position of the first peak was similar for G1A, G2A, G1B, G2B, G3B and the normal (438 nm); that for G3A was
shifted to a longer wavelength (444 nm) compared to the normal. The position of the second peak was similar for
G1A, G1B, G2A, G2B and the control (487 nm), while it was shifted to a shorter wavelength for G3A (483 nm) and
G3B (483 nm). The fluorescence intensity of the first and second peaks increased for G1A, G2A, G1B and G2B, while
it decreased for G3A and G3B compared to the control.
Conclusions: The fluorescence intensity of GNPs varied with the number, size and shape of particles and with the
ratio of surface area to volume in a given sample. Fluorescence intensity changes during infusion depended on
the size and shape of GNPs, with smaller particles experiencing larger changes during the infusion time in addition
to the quenching produced by the larger GNPs. It is likely that smaller particles, which have a much higher ratio of
surface area to volume compared to larger particles, are more prone to aggregation and surface interaction with
biological components. This study suggests that fluorescence intensity can be used to evaluate bioaccumulation
and the toxicity of gold nanoparticles in rats.
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Nanoparticles (NPs) offer great promise for biomedical
applications, particularly in pharmaceutical delivery and
novel diagnostic and therapeutic methods [1].
Despite the many potential therapeutic benefits of nano-
particles, some studies indicate that certain nanoparticles,
due to their small size and unique physical properties, may
cause adverse effects [2,3]. The size, surface area and
dosage of particles all appear to play important roles in
mediating nanoparticle toxicity. It has been proposed, for
example, that the size of nanoparticles influences their
adhesion to and interaction with living cells [4].
The small size of NPs may enable interactions with spe-
cific biological targets. Furthermore, metallic NPs can be
made to exhibit a resonant response to a time-dependent
magnetic field, producing a potentially useful energy trans-
fer to the particles [5,6]. Therefore, such particles have
been used as hyperthermic agents that deliver lethal
amounts of thermal energy to targets such as tumours
[7-9].
Gold NPs (GNPs) show several features that make
them well suited for biomedical applications, including
straightforward synthesis, stability, and the potential for
surface modification with active biological molecules
such as peptides or proteins [5].
Semmler-Behnke et al. observed that a considerable
percentage of 18 nm GNPs is removed from the blood
and trapped predominantly in the liver and spleen [10].
Fluorescence is the emission of light by a substance fol-
lowing absorption of light or other electromagnetic radia-
tion of a different wavelength. In most cases, the emitted
light has a longer wavelength, and therefore lower energy,
than the absorbed radiation. However, when the absorbed
electromagnetic radiation is intense, it is possible for one
molecule to absorb two photons; this two-photon absorp-
tion can lead to emission of radiation having a shorter
wavelength than the absorbed radiation.
The origin of the unique optical properties of GNPs is a
phenomenon known as surface plasmon resonance (SPR).
The exposure of nanoparticles to electromagnetic radia-
tion of a wavelength much smaller than the GNP diameter
induces coherent, resonant oscillations of the conduction-
band electrons across the nanoparticles. These oscillations
are known as the SPR, which lies in the visible frequency
range and results in strong optical absorbance and scatter-
ing by the GNPs [11,12]. This phenomenon has been
exploited in many applications of GNPs, such as Raman
sensors [13], photocatalysts [14], and photoelectrochem-
ical materials [15,16]. In the bioscience and medical fields,
GNPs are used as immunostaining labels for electron
microscopy and as chromophores for immunoreactions
and nucleic acid hybridisation [17,18].
Despite these many useful applications of NPs, numer-
ous studies have shown that exposure to smaller-sized
particles produces greater inflammatory and cytotoxic
responses compared to exposures to larger-sized parti-
cles at the same mass concentration [19]. It is believed
that smaller-sized particles are more reactive with biolo-
gical components and produce adverse effects due to
the large surface area and large number of particles in a
nanoparticle preparation compared to a larger-particle
preparation [20].
T h et o x i c i t yo fN P si st h o u g h tt od e p e n do nt h es i z e ,
surface area, composition, and shape of the nanomaterial.
Particle size plays a role in how the body responds to, dis-
tributes, and eliminates materials [14,15]; it can also affect
the mode of endocytosis and cellular uptake and the effi-
ciency of particle processing in the endocytic pathway
[21,22]. Therefore, for applications of GNPs in therapy
and drug delivery, it is necessary to know the bioaccumu-
lation and local or systemic toxicity associated with the
nanoparticles.
The particle-size-dependent organ distribution of GNPs
has been studied in vivo [23-26]. Hyllier and Albertch
showed that orally administered GNPs appeared in various
tissues in mice, and that smaller particles were more read-
ily absorbed and more widely distributed in the body than
were larger particles [23]. In most studies, systemically
administered NPs were primarily taken up by the liver and
spleen, with lesser quantities taken up by the lung, kidney,
heart, and brain after a single administration. However, lit-
tle is known about the biodistribution, accumulation and
toxicity of GNPs after repeated administration.
GNPs can be used in various biomedical applications;
however, very little is known about the size, dose and
exposure dependence of in vivo nanoparticle processing
kinetics. Furthermore, there are currently no data available
regarding the fluorescence spectra and accumulation of
nanoparticles (NPs) in rat liver following repeated in vivo
administration.
Materials and methods
Gold nanoparticles (GNPs)
GNPs of different sizes (10, 20 and 50 nm; products
MKN-Au-010, MKN-Au-020 and MKN-Au-050, Canada,
respectively) were purchased. All GNPs used in this study
were in aqueous solution at a concentration of 0.01%. The
mean size and morphology of these GNPs were evaluated
from transmission electron microscope (TEM) images.
The high electron density of gold makes this method par-
ticularly suitable for evaluating the homogeneity of the
nanoparticles in terms of shape and size.
Animals
Healthy male Wistar-Kyoto rats were obtained from the
L a b o r a t o r yA n i m a lC e n t r e( C o l l e g eo fP h a r m a c y ,K i n g
Saud University). Rats of age 8-12 weeks (approximately
250 g body weight) were housed in pairs in humidity- and
Abdelhalim and Mady Lipids in Health and Disease 2011, 10:195
http://www.lipidworld.com/content/10/1/195
Page 2 of 9temperature-controlled ventilated cages on a 12 h day/
night cycle. A conventional rodent diet and water were
provided. Forty rats were individually caged and divided
into a control group (NG: n = 10), group 1 (A: infusion of
20 nm GNPs for 3 days; n = 5; B: infusion of 20 nm GNPs
for 7 days; n = 5), group 2 (A: infusion of 10 nm GNPs for
3 days; n = 5; B: infusion of 10 nm GNPs for 7 days; n = 5)
and group 3 (A: infusion of 50 nm GNPs for 3 days; n = 5;
B: infusion of 50 nm GNPs for 7 days; n = 5). In addition,
histological investigations of 10 rats were performed in
support of this study. Doses (50 μl) of 10, 20 or 50 nm
GNPs in aqueous solution were administered to the ani-
mals via intraperitoneal injection every day for 3 or 7 days.
The rats were anesthetised by inhalation of 5% isoflurane
until muscular tonus relaxed. Blood and liver tissue were
collected from each rat. A blood sample of approximately
1 ml was obtained from each rat via venepuncture of an
antecubital vein; the blood was mixed with 0.8 ml of
heparin to prevent coagulation. In order to assess tissue
uptake, as much blood as possible was collected from the
rats to maximise residual blood drainage from the organs.
All experiments were conducted in accordance with
guidelines approved by the King Saud University Local
Animal Care and Use Committee.
Digestion of liver tissue samples
Liver tissue samples were wet-digested with nitric acid
and stored as acidic digest solutions for analysis by fluor-
escence spectroscopy. The liver tissue was first freeze
dried to minimise analyse loss and to facilitate subse-
quent sample preparation steps. The tissue was then
homogenised to a fine powder by ball-milling in plastic
containers. Approximately 0.20-0.25 g of powdered tissue
was weighed into a Teflon reaction vessel and 3 ml of
HNO3 was added. The closed reaction vessel was heated
in a 130°C oven until digestion was completed. Samples
were then diluted to a final volume of 20 ml with quartz-
distilled water and stored in 1 oz. polyethylene bottles for
subsequent fluorescence spectroscopy analysis.
Fluorescence spectroscopy
Fluorescence spectra of liver tissue containing GNPs of
different sizes (10, 20 or 50 nm) were obtained using a
FluoroMax-2 spectrofluorometer (JOBIAN YVON-SPEX,
I n s t r u m e n t sS .A . ,I n c . ,F r a nce). Fluorescence measure-
ments were made over the wavelength range 250-700 nm
using 1 cm path length quartz cuvettes, which were
cleaned before each use by sonicating for 5 min in deio-
nised water and then rinsing with deionised water.
Results and discussion
Size and morphology of different GNPs
The 10 and 20 nm GNPs showed spherical morphology
with a narrow particle size distribution when dispersed in
solution. The mean size for these GNPs was calculated
from the TEM images. The mean measured size was
9.45 ± 1.33 nm for 10 nm GNPs and 20.18 ± 1.80 nm for
20 nm GNPs. GNPs of 50 nm diameters, in contrast, were
not spherical but hexagonal in TEM images, as shown in
Figure 1. The high electron density and homogeneous
shape and size of the GNPs make them highly conspicu-
ous under the TEM.
The maximum of the surface plasmon band (SPB) of
GNPs in solution was shifted from 517 nm to 532 nm
when the GNP size changed from 10 nm to 50 nm. This
effect was attributed to the surface plasmon oscillation of
free electrons. After injecting 20 nm GNPs into the
experimental rats, we observed two fluorescence peaks at
438 nm and 487 nm in the digested liver tissue.
Figures 2 and 3 show fluorescence spectra for 20 and 10
nm GNPs, respectively, following infusion periods of 3
and 7 days. The results show that the positions of the first
and second peaks were nearly the same for G1A, G1B,
G2A and G2B compared with the control while the fluor-
escence intensity for these peaks (both first and second)
increased with increasing infusion period compared to the
control.
Figure 4 shows fluorescence spectra for 50 nm GNPs
following infusion periods of 3 and 7 days. The position
of the first peak shifted to a longer wavelength (first
peak: 444 nm) and the second to a shorter wavelength
(second peak: 483 nm) for G3A compared to the normal.
However, the position of the first peak was the same as
control for G3B, and the second peak shifted to a shorter
wavelength (483 nm) compared to the normal. The fluor-
escence intensity of GNPs was lower for G3A (both first
a n ds e c o n dp e a k s )a n dm u c hl o w e rf o rG 3 B( b o t hf i r s t
and second peaks) compared to the control. This result
may be attributed to any of three factors: 1) formation of
a strong ground state complex between serum albumins
and gold nanoparticles (static quenching); 2) differences
in the physical and chemical properties of nanoparticles
of different size and shape (as noted above, most 50 nm
GNPs were hexagonal, and nanoparticle properties are
highly size- and shape-dependent); or 3) faster uptake of
and clearance by liver macrophages of the 50 nm GNPs
compared to the other nanoparticles.
Figures 5 and 6 show fluorescence spectra for 10, 20
and 50 nm GNPs following infusion periods of 3 and 7
days, respectively.
Figure 5 shows the effect of particle size on GNP fluor-
escence spectra after an infusion period of 3 days (G1A,
G2A and G3A). The first peak appears at a longer wave-
length for G3A (444 nm) compared to the other samples,
in which the first peak is at nearly the same position as
the normal. The second peak appears at nearly the same
position for G1A, G2A and the normal, while that of
G3A is shifted to shorter wavelength (483 nm). The
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compared to the normal, while that in the G3A spectrum
was lower.
F i g u r e6s h o w st h er e s u l t so ft h es a m ee x p e r i m e n t
after an infusion period of 7 days. The position of the
first peak is nearly the same for G1B, G2B, G3B and the
normal, while the position of the second peak is nearly
the same for G1B, G2B and the normal, while the G3B
peak is shifted to a shorter wavelength (483 nm). The
intensity of both peaks was higher for G1B and G2B
than for the normal, while the intensity of these peaks
in the G3B spectrum was lower.
Figure 7 shows the effect of size on the fluorescence
spectra of GNPs after infusion periods of 3 days (G1A,
G2A and G3A) and 7 days (G1B, G2B and G3B). The
first peak is shifted to a longer wavelength for G3A (444
nm) but is nearly the same for all other samples com-
pared to the normal. The second peak is at nearly the
same position for G1A, G1B, G2A, G2B and the normal,
w h i l ei ti ss h i f t e dt oas h o r t e rw a v e l e n g t hf o rG 3 Aa n d
G3B. The intensity of both peaks is higher for G1A,
G2A, G1B and G2B and lower for G3A and G3B com-
pared to the normal.
Nanotechnology has recently emerged as a promising
field for the treatment and diagnosis of a variety of dis-
eases [1]. GNPs are particularly promising because of
their ease of synthesis in various shapes and the poten-
tial for conjugation with peptides and proteins, which
can target the GNPs to specific interaction partners [6].
The results of this study indicate that decreasing
nanoparticle size, which produces an exponential
i n c r e a s ei ns u r f a c ea r e ar e l a t i v et ov o l u m e ,m a ym a k e
the GNPs more self-reactive (i.e., may promote aggrega-
tion) and more prone to interactions with surrounding
molecules (biological components). Moreover, increased
uptake of nanoparticles may lead to accumulation in
certain tissues, where the particles may interfere with
critical biological functions [16,21]. We note that the
rate of exocytosis of GNPs is size dependent; larger
GNPs are more readily accumulated in the cell [27].
To evaluate the time dependence of GNP distribution
and aggregation, we administered 50 μlo fG N P so f( 1 0 ,
20 and 50 nm) by daily intraperitoneal injection into
rats for periods of 3 or 7 days. At these time points, the
bio-distribution of the GNPs was quantitatively mea-
s u r e db yf l u o r e s c e n c es p e c t r o s c o p ya n dT E M .T h es i z e
of the GNPs strongly influenced the bio-distribution.
The very small size of nanoparticles imparts physical
and chemical properties that are very different from
those of the same material in bulk form. Nanoparticles
have a larger surface area to volume ratio compared to
bulk materials; they may thus exhibit an enhanced or
hindered tendency to aggregate (depending on the sur-
face chemistry), enhanced photoemission, high electrical
or heat conductivity, or improved surface catalytic activ-
ity [19,21].
10 nm 
20 nm 
50 nm 
Figure 1 TEM images for different GNP samples.
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gical components, nanoparticles may be more reactive
than larger particles toward biomolecules. It has been
shown, for example, that the severity and the likelihood
of inflammatory response transiently increased, within
12 h, following injection of 200 or 100 nm GNPs into
experimental animals. GNPs were ultimately trapped
by macrophages in the spleen and liver and remained
in these tissues until 4 weeks after the single injection
[17].
To evaluate the impact of particle size on tissue distri-
bution, we injected rats with 50 μl GNPs of different
sizes. The 50 nm GNPs were taken up by liver macro-
phages faster and to a greater extent than smaller GNPs;
the particles were eliminated after uptake. This result is
correlated with the inflammatory response of the liver.
350 400 450 500 550 600 650 700 750 800
-10000
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
F
l
u
o
r
e
s
c
e
n
c
e
 
I
n
t
e
n
s
i
t
y
Wavelength (nm)
Excitation at 385.5 nm
 Refrence
 Normal
 G1A (20 nm & 3 days)
 G1B (20 nm & 7 days)
Figure 2 The fluorescence emission peak intensity after infusion periods of 3 and 7 days for 20 nm GNPs.
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Figure 3 The fluorescence emission peak intensity after infusion periods of 3 and 7 days for 10 nm GNPs.
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cleared via urine and bile rapidly. Nanoparticles for thera-
peutic use need to have a long retention time in order to
encounter and interact with the desired target. However, a
long retention time can result in toxic effects in vivo.
Thus, route and rate of nanomaterial clearance is an
important issue [28,29].
Absorbed nanoparticles in the systemic circulation can
be excreted through various routes, such as the kidneys or
bile. Renal clearance of solid nano-sized materials is
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Figure 4 The fluorescence emission peak intensity after infusion periods of 3 and 7 days for 50 nm GNPs.
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Figure 5 The fluorescence emission peak intensity after infusion period of 3 days for 10, 20 and 50 nm GNPs.
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Page 6 of 9known to be influenced by particle size and surface charge
[29,30]. In the present study, we monitored the fluores-
cence intensity and tissue distribution of three different
GNP preparations of varying particle size after intravenous
injection into rats over periods of 3 or 7 days. We found
that GNP fluorescence intensity and liver tissue distribu-
tion varied with particle size. The fluorescence intensity
for 10 and 20 nm GNPs increased as the infusion period
increased from 3 to 7 days, while it decreased during this
period for 50 nm GNPs. Larger-sized particles gave lower
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Figure 6 The fluorescence emission peak intensity after infusion period of 7 days for 10, 20 and 50 nm GNPs.
350 400 450 500 550 600 650 700 750 800
-10000
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
130000
140000
150000
F
l
u
o
r
e
s
c
e
n
c
e
 
I
n
t
e
n
s
i
t
y
Wavelength (nm)
 Refrence
 Normal
 G1A (20 nm & 3 days)
 G1B (20 nm & 7 days)
 G2A (10 nm & 3 days)
 G2B (10 nm & 7 days)
 G3A (50 nm & 3 days)
 G3B (50 nm & 7 days)
Figure 7 The fluorescence emission peak intensity after infusion periods of 3 and 7 days for 10, 20 and 50 nm GNPs.
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Page 7 of 9fluorescence intensity because more particles were trapped
by macrophages.
All GNPs showed a propensity to accumulate in tis-
sues following injection. The liver tissue distribution of
GNPs was size dependent: the smallest particles showed
the most widespread organ distribution. Smaller GNPs
also showed greater accumulation in cells according to
dose-metric treatment. Therefore, it should be taken
into consideration that GNPs preferentially target organs
with many phagocytic cells, such as kidney, spleen, lung,
heart and mesenteric lymph nodes.
Conclusions
High electron density and homogeneous shape and size
make GNPs highly conspicuous in TEM images. We
f o u n dt h a tt h e1 0a n d2 0n mG N Pp r e p a r a t i o n se x h i b i t
spherical morphology, while 50 nm GNPs are hexagonal.
The size (i.e., surface area to volume ratio), shape and
concentration of GNPs all contributed to differences in
the fluorescence intensities between GNP samples. The
time dependence of GNP fluorescence spectra was also
dependent on these factors; smaller particles generally
exhibited higher fluorescence that increased with GNP
infusion time, whereas larger GNPs exhibited lower fluor-
escence decreasing with infusion time.
This study suggests that fluorescence intensity may be a
useful diagnostic probe for bioaccumulation and toxicity
of gold nanoparticles administered to rats. Moreover,
smaller particles, which have an increased ratio of surface
area to volume, appear to be more reactive toward one
another (resulting in aggregation) and toward biological
components in the surrounding environment.
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